Company profile
Mica Biosystems Limited
Regenerative Medicine | MICA Biosystems
Home of remote-controlled cell therapy developed by world-leading scientists. MICA Biosystems also offers research instrumentation for cell mechanostimulation, and a drug screening platform, acting as an add-on to Caco-2 assays.
Latest accounts
Financial period: 1 May 2024 to 30 Apr 2025
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Termination Director Company With Name Termination Date
OfficersTM01 | Transaction MzQzNzk4MDE3NGFkaXF6a2N4
Published 01 Oct 2024 02:59
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Enhancing Drug Discovery: Revolutionising Permeability Predictions with Dynascreen
1 Jan 2025 to 31 Mar 2025
MICA Biosystems is leading an exciting project to improve the traditional static Caco-2 assay, a key method for testing how drugs are absorbed in the body. We are introducing magnetic nanoparticles to make this test more dynamic, simulating the natural movements in the human gut. This innovation is important for the pharmaceutical industry because it brid...
A novel therapy for treatment of degenerative spinal conditions
1 Mar 2022 to 29 Feb 2024
Low back (LBP) pain and Chronic Low Back Pain (CLBP) represent a common condition linked to musculoskeletal diseases, which affect aged population and represent a major social and economic problem in developed countries. LBP is more common among people aged 40--80 years. The overall number of individuals affected is expected to increase as the population ...
Commercial translation of a dynamic ADME screening platform,.DYNASCREEN.
1 Jun 2017 to 30 Nov 2017
The Caco-2 cell line used by the pharmaceutical industry and support companies is the gold standard for the prediction of drug absorption and permeability in vitro by mimicking the small intestine. However, this model lacks the dynamic motion which represents one of the physiological functions of the small intestine (peristalsis). Our new product developm...
Development and validation of a dynamic drug screening platform for ADME testing .
1 Oct 2014 to 30 Jun 2016
The Caco-2 cell line is the gold standard for the prediction of drug absorption and permeability in vitro by mimicking the small intestine. However, this model lacks the dynamic motion which represents one of the physiological functions of the small intestine (peristalsis). In our research, we investigate the possibility the similarity between the static ...